Enclomiphene 25 mg

Enclomiphene 25 mg contains enclomiphene, a SERM. In clinical research it has been investigated for secondary hypogonadism. In non-medical bodybuilding contexts, it is commonly referenced as a post-cycle therapy agent or for stimulating endogenous testosterone production. Such use falls outside approved medical indications.

Enclomiphene is typically referenced at once daily dosing. In clinical studies, doses of 6.25–25 mg daily have been investigated. In non-medical bodybuilding contexts, common reference points are 12.5–25 mg daily, though dosing should be individualized.

Enclomiphene itself is commonly used as a PCT agent, so it is not typically followed by additional PCT. After a suppressive cycle, enclomiphene can help stimulate endogenous testosterone production by blocking estrogen feedback. It may be used alongside other recovery agents like Nolvadex if desired.

Enclomiphene blocks estrogen receptors in the hypothalamus, which reduces negative feedback on gonadotropin-releasing hormone. This leads to increased LH and FSH release, stimulating the testes to produce more testosterone. It is the pure trans-isomer of clomiphene citrate.

Enclomiphene begins affecting the hypothalamic-pituitary axis shortly after administration, though full effects on testosterone levels typically develop over days to weeks. Bloodwork can confirm whether LH, FSH, and testosterone levels are responding as expected.

There is no single SERM that is universally best for PCT. Enclomiphene is the pure trans-isomer of clomiphene and has been reported to have a lower rate of adverse effects compared to clomiphene citrate. Other options like Nolvadex and Clomid are also commonly referenced, and the appropriate choice depends on individual response and circumstances.

Clomiphene citrate is a mixture of two isomers: enclomiphene (trans-isomer) and zuclomiphene (cis-isomer). Enclomiphene is the pure trans-isomer, while zuclomiphene has been associated with more estrogenic side effects. Research suggests enclomiphene provides comparable testosterone increases with fewer adverse effects.

Enclomiphene and Nolvadex are both SERMs used in PCT contexts, but they have different tissue selectivity profiles and pharmacokinetics. Enclomiphene is the pure trans-isomer of clomiphene, while Nolvadex is tamoxifen. Both can stimulate LH and FSH, but individual response and side effect profiles may differ.

In clinical research, 25 mg daily has been studied as a standard dose for secondary hypogonadism. In non-medical bodybuilding contexts, common reference points range from 12.5–25 mg daily. The 25 mg strength of Enclomiphene 25 mg allows for splitting to achieve lower doses if desired.

Enclomiphene 25 mg is labeled at 25 mg of enclomiphene per tablet. It is supplied in a 100-tablet package, giving 2,500 mg of total labeled enclomiphene content.

Yes. A published laboratory report dated October 16, 2025 measured Enclomiphene 25 mg at 25.19 mg/tablet, equivalent to 100.76% of its 25 mg label claim. The batch number for this report was #HDENC9. The complete report can be viewed in the Lab Reports tab.

Clinical research has investigated enclomiphene for its ability to stimulate testosterone production while preserving sperm counts, in contrast to exogenous testosterone which suppresses sperm production. This fertility-preserving characteristic is one of the distinguishing features of enclomiphene compared to traditional testosterone replacement.